EULAV Asset Management’s AbbVie ABBV Stock Holding History

EULAV Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-29,000	Closed	-$1.66M	–	273
2016 Q1	$1.66M	Sell	29,000 -12,000	-29%	-$669K	0.09%	222
2015 Q4	$2.43M	Sell	41,000 -49,000	-54%	-$2.82M	0.13%	188
2015 Q3	$4.9M	Hold	90,000	–	–	0.28%	127
2015 Q2	$6.05M	Hold	90,000	–	–	0.32%	112
2015 Q1	$5.27M	Buy	90,000 +18,000	+25%	+$1.09M	0.27%	130
2014 Q4	$4.71M	Buy	72,000 +4,000	+6%	+$252K	0.25%	142
2014 Q3	$3.93M	Buy	68,000 +33,000	+94%	+$1.83M	0.21%	157
2014 Q2	$1.98M	Buy	+35,000	New	+$1.84M	0.11%	257

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

EULAV Asset Management's ABBV Position: Q2 2016 in Review

EULAV Asset Management sold out of AbbVie (ABBV) in Q2 2016, closing a stake of 29,000 shares — an estimated $1.66M sold.

EULAV Asset Management first reported a position in ABBV in Q2 2014 and held it in 8 quarters. The position peaked at $6.05M in Q2 2015. 1,636 funds tracked by Wall St. Rank hold ABBV as of Q2 2016.

EULAV Asset Management reported no remaining AbbVie position as of Q2 2016 after selling out during the quarter.
EULAV Asset Management sold 29,000 AbbVie shares in Q2 2016, an estimated $1.66M.
EULAV Asset Management first reported a position in AbbVie in Q2 2014 and held it in 8 quarters.
EULAV Asset Management's AbbVie position peaked at $6.05M in Q2 2015.
1,636 funds tracked by Wall St. Rank held AbbVie as of Q2 2016.

Based on EULAV Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.